Literature DB >> 11980

A method for the measurement of L-phenylalanine mustard in the mouse and dog by high-pressure liquid chromatography.

R L Furner, L B Mellett, R K Brown, G Duncan.   

Abstract

The distribution of L-phenylalanine mustard (L-PAM) was studied in dogs and mice by high-pressure liquid chromatography. Separation of L-PAM from its products of hydrolysis was accomplished with a mu-Bondapak C18 column, a solvent system composed of 2-methoxyethanol/0.1% acetic acid, and solvent programming with a step gradient. Complete separation was effected in less than 15 min. The half-life for disappearance of L-PAM from mouse blood was 41 min, whereas that from dog blood was 29 min. The monohydroxy derivative of L-PAM, L-MOH, disappeared from dog serum with a half-life of 32 min. L-MOH was not detectable in mouse tissue other than blood at times greater than 15 min after injection. In the dog at 4 hr after injection, the tissue/serum concentration ratios were greater than 1 for liver, spleen, intestine, skeletal muscle, urinary bladder and gallbladder. The concentration of L-PAM in the bile was approximately 500 times higher than that in serum.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 11980

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits.

Authors:  I A Taha; R A Ahmad; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

3.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.

Authors:  P E Noker; L Simpson-Herren; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Pharmacokinetics of high-dose melphalan in children and adults.

Authors:  A Gouyette; O Hartmann; J L Pico
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  In vitro degradation of L-phenylalanine mustard (L-PAM).

Authors:  T L Evans; S Y Chang; D S Alberts; I G Sipes; K Brendel
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays.

Authors:  A G Bosanquet; M C Bird
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 8.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity.

Authors:  L Simpson-Herren; P E Noker; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.

Authors:  D J Honess; J Donaldson; P Workman; N M Bleehen
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.